Patent intelligence · US
US 6544528
Multi-subtype FIV vaccines
Multi-subtype FIV vaccines
Patent details — US 6544528
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 8, 2003
- Expiration
- Apr 3, 2023
- Applicant
- THE REGENTS OF THE UNIV. OF CALIFORNIA
- Claims
- 33
- CPC classes
- A61K, A61K2039/515, A61K2039/5252, A61K2039/545
Quick answer
US 6544528 (Multi-subtype FIV vaccines) is held by THE REGENTS OF THE UNIV. OF CALIFORNIA. Status: expired. Granted Apr 8, 2003. Expires Apr 3, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- THE REGENTS OF THE UNIV. OF CALIFORNIA
- Grant date
- Expiration
- Claims
- 33
- CPC classes
- A61K, A61K2039/515, A61K2039/5252, A61K2039/545, A61K2039/57, A61K39/12
More from THE REGENTS OF THE UNIV. OF CALIFORNIA
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 6544528?
US 6544528 (Multi-subtype FIV vaccines) is held by THE REGENTS OF THE UNIV. OF CALIFORNIA. Status: expired. Granted Apr 8, 2003. Expires Apr 3, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6544528?
THE REGENTS OF THE UNIV. OF CALIFORNIA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 6544528 expire?
Our index shows an expiration date of Apr 3, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.